Trial Profile
Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections; Respiratory tract infections
- Focus Therapeutic Use
- 15 Sep 2023 Planned End Date changed from 1 Sep 2023 to 1 Apr 2024.
- 15 Sep 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.
- 14 Mar 2023 Planned End Date changed from 1 Mar 2023 to 1 Sep 2023.